Showing 5041-5050 of 21466 results for "".
- AI-Guided CRISPR Finds New Psoriasis Targets in Keratinocyteshttps://reachmd.com/news/ai-guided-crispr-finds-new-psoriasis-targets-in-keratinocytes/2487918/Key Takeaways Zhao et al. described the first genome-wide CRISPR study in primary adult human skin cells, generating an IL17RA-focused regulatory map in keratinocytes that the authors framed as relevant to psoriasis biology. VirtualCRISPR prioritized underrecognized
- FDA Expands Ryaltris Use in Children Aged 6 to 11 Yearshttps://reachmd.com/news/fda-expands-ryaltris-use-in-children-aged-6-to-11-years/2487904/Key Takeaways The expanded indication now includes pediatric patients aged 6 to younger than 12 years with seasonal allergic rhinitis. In a 446-patient phase 3 randomized, double-blind, placebo-controlled study, twice-daily dosing for 14 days was ass
- Efgartigimod in Sjögren's Disease: Phase 2 RHO Trial Resultshttps://reachmd.com/news/efgartigimod-in-sjogrens-disease-phase-2-rho-trial-results/2487905/Key Takeaways At week 24, CRESS response was higher with intravenous efgartigimod than with placebo. cSTAR response also favored efgartigimod, which scored higher on four of five CRESS items. Treatment-emergent adverse events were more common
- 0/1-Hour vs 0/3-Hour Troponin Pathways in Suspected ACShttps://reachmd.com/news/01-hour-vs-03-hour-troponin-pathways-in-suspected-acs/2487915/Key Takeaways The 0/1-hour pathway was not associated with a significant increase in discharge within 4 hours. The 0/1-hour pathway was noninferior for 30-day discharge safety among discharged patients considered not to have ACS. The authors a
- Sanofi Halts Amlitelimab Development in Atopic Dermatitishttps://reachmd.com/news/sanofi-halts-amlitelimab-development-in-atopic-dermatitis/2487921/Sanofi has announced it will discontinue the clinical development of amlitelimab for moderate-to-severe atopic dermatitis (AD), ending plans to submit the investigational therapy for global regulatory review after determining it would not provide a meaningful adva
- Tapinarof Demonstrates Consistent Efficacy Across Pediatric and Adult Patients With Atopic Dermatitishttps://reachmd.com/news/tapinarof-demonstrates-consistent-efficacy-across-pediatric-and-adult-patients-with-atopic-dermatitis/2487900/Organon will present new data from a post hoc pooled analysis of the Phase 3 ADORING 1 and ADORING 2 trials at the 2026 Society for Pediatric Dermatology (SPD) Annual Meeting in Minneapolis, Minnesota, showing that tapinarof (VTAMA) cream 1% produced early and consistent improvements in patients
- Zalfermin Plus Semaglutide Misses Fibrosis Endpoint in Phase 2 MASH Trialhttps://reachmd.com/news/zalfermin-plus-semaglutide-misses-fibrosis-endpoint-in-phase-2-mash-trial/2487898/Key Takeaways The zalfermin-plus-semaglutide combination did not significantly improve the primary endpoint versus placebo. Semaglutide monotherapy was associated with a nominally significant signal on the same endpoint at week 52. Adverse eve
- Lebrikizumab Meets Primary Endpoints in Phase 3 ADorable-1 Trial for Pediatric Atopic Dermatitishttps://reachmd.com/news/lebrikizumab-meets-primary-endpoints-in-phase-3-adorable-1-trial-for-pediatric-atopic-dermatitis/2487891/Lebrikizumab demonstrated significant improvements in disease severity and symptoms in infants, children, and adolescents with moderate-to-severe atopic dermatitis (AD), according to Week 16 results from the phase 3 ADorable-1 trial presented at the 2026 Society f
- Swiss Skincare Brand Launches Personalized Art of Longevity Programhttps://reachmd.com/news/swiss-skincare-brand-launches-personalized-art-of-longevity-program/2487890/Swiss skincare company Valmont has introduced The Art of Longevity, a personalized program designed to integrate genetic analysis, lifestyle assessment, and professional skincare into an individualized longevity strategy. According to the company, the initiative was developed by Valmont CE
- Biologic Strategies for Noninfectious Uveitis in a Randomized Trialhttps://reachmd.com/news/biologic-noninfectious-uveitis-randomized-trial/2487884/Key Takeaways Adalimumab and tocilizumab reached the week 16 corticosteroid-sparing endpoint at similar observed rates of 16% and 14%, respectively. Interim analyses found anakinra ineffective. Mild to moderate adverse events were reported in 43% and 5